Kazia Therapeutics Limited (KZIA)

NASDAQ: KZIA · IEX Real-Time Price · USD
1.16
+0.03 (2.65%)
Sep 26, 2022 4:00 PM EDT - Market closed
2.65%
Market Cap 21.02M
Revenue (ttm) 10.89M
Net Income (ttm) -10.77M
Shares Out 18.12M
EPS (ttm) -0.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,661
Open 1.16
Previous Close 1.13
Day's Range 1.14 - 1.21
52-Week Range 1.04 - 12.28
Beta 2.88
Analysts Buy
Price Target 3.24 (+179.3%)
Earnings Date Oct 6, 2022

About KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Austr... [Read more...]

Industry Biotechnology
IPO Date Jan 6, 1999
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol KZIA
Full Company Profile

Financial Performance

In 2021, KZIA's revenue was 15.23 million, an increase of 1,335.16% compared to the previous year's 1.06 million. Losses were -8.42 million, -32.45% less than in 2020.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for KZIA stock is "Buy." The 12-month stock price forecast is 3.24, which is an increase of 179.31% from the latest price.

Price Target
$3.24
(179.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Novogen Limited (KZIA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean...

22 hours ago - Zacks Investment Research

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE

SYDNEY , Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presen...

2 weeks ago - PRNewsWire

KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO

SYDNEY , Sept. 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxal...

2 weeks ago - PRNewsWire

Kazia Therapeutics (KZIA): Doubling Down on Clinical Development

LONDON, UK / ACCESSWIRE / September 7, 2022 / Kazia Therapeutics' FY22 results recapped a busy year focused on strengthening its oncology-focused pipeline. While the year was marked by encouraging data ...

2 weeks ago - Accesswire

Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Novogen Limited (KZIA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate r...

1 month ago - Zacks Investment Research

KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT ...

SYDNEY , Aug. 5, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new data fro...

1 month ago - PRNewsWire

KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER

SYDNEY , July 12, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Boa...

2 months ago - PRNewsWire

Kazia Therapeutics (KZIA) Stock Soars on FDA Designation

Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment. The post Kazia Therapeutics (KZIA) Stock Soars on FDA Designation appeared ...

2 months ago - InvestorPlace

US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY , July 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Admin...

2 months ago - PRNewsWire

US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY , June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Admi...

3 months ago - PRNewsWire

POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING

SYDNEY , June 13, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding th...

3 months ago - PRNewsWire

PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT

SYDNEY , June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple ther...

3 months ago - PRNewsWire

KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE

SYDNEY , June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxa...

3 months ago - PRNewsWire

GBM AGILE OPENS TO PAXALISIB IN EUROPE

SYDNEY , May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (...

3 months ago - PRNewsWire

Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer

LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address a...

4 months ago - Accesswire

KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO

SYDNEY , May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be present...

4 months ago - PRNewsWire

KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

SYDNEY , May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless...

4 months ago - PRNewsWire

KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO

SYDNEY , April 29, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxa...

4 months ago - PRNewsWire

KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVI...

SYDNEY , April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce new preclinical data demonstrating the ac...

5 months ago - PRNewsWire

TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I ...

SYDNEY , April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing th...

5 months ago - PRNewsWire

KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING

SYDNEY, March 21, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two ...

6 months ago - PRNewsWire

PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A K...

SYDNEY, Feb. 28, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investiga...

6 months ago - PRNewsWire

KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE

SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenti...

7 months ago - PRNewsWire

KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE

SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speakin...

8 months ago - PRNewsWire

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE

SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking...

8 months ago - PRNewsWire